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Pancreatic cancer is one of the most lethal of all cancers. The 
median survival is six months and less than 5% of those diagnosed 
survive five years. Recurrent genetic deletions and amplifications 
in 72 pancreatic adenocarcinomas, the largest sample set analyzed 
to date for pancreatic cancer, were defined using comparative 
genomic hybridization The recurrent genetic alterations identified 
target a number of previously well-characterized genes, as well as 
regions that contain possible new oncogenes and tumor suppressor 
genes. We have focused on chromosome 19q13, a region frequently 
found amplified in pancreatic cancer and demonstrate how bound-
aries of common regions of mutation can be mapped and how a 
gene, in this case PAK4 amplified on chromosome19q13, can b  
functionally validated. We show that although the PAK4 gene is 
not activated by mutation in cell lines with gene amplification, an 
oncogenic form of the KRAS2 gene is present in these cells and 
oncogenic KRAS2 can activate PAK4. In fact in the three samples 
we identified with PAK4 gene amplification, the KRAS2 gene was 
activated and genomically amplified. The kinase activity of the 
PAK4 protein is significantly higher in cells with genomic ampli-
fication as compared to cells without amplification. Our study 
demonstrates the utility of analyzing copy number data in a large 
set of neoplasms to identify genes involved in cancer. We have 
generated a useful dataset which will be particularly useful for the 
pancreatic cancer community as efforts are undertaken to sequence 
the pancreatic cancer genome.
Introduction
It has been estimated that this year 37,680 Americans will 
be diagnosed with pancreatic cancer and that 34,290 Americans 
will die from this disease (see www.cancer.org/downloads/STT/
CAFF2008PWSecured.pdf ).1 The five year survival rate for pancre-
atic cancer is one of the lowest of all the solid malignancies, with a 
less than 5% five year survival rate. It should not be surprising that 
pancreatic cancer is the fourth leading cause of cancer death in the 
United States. Most existing therapies are of marginal efficacy. They 
do little to extend survival or alleviate pain and that do not cure the 
patient. At the same time, novel approaches have been developed to 
target genetic differences between cancer and normal cells, including 
the synthetic lethal screening methodology described by L. Hartwell.2 
For example, the methylthioadenosine phosphorylase (MTAP) gene 
on chromosome 9p is frequently included in homozygous deletions 
targeting the p16/CDKN2A gene in pancreatic cancer.3 The deletion 
of the MTAP gene in pancreatic cancers deletes a critical gene in the 
synthesis of AMP, making these cancer cells selectively sensitive to 
inhibitors of the salvage pathway for AMP biosynthesis.
Deletions and amplifications can be accurately identified by array 
based comparative genomic hybridization (CGH). There are several 
different array formats for CGH available. These arrays differ in 
the material utilized for probes, cDNA fragments,4 BAC DNA or 
representations of BAC DNAs,5 or oligonucleotides, but most rely 
on total genome or whole genome amplifications of total genome for 
hybridization. We have developed representational methods for array 
CGH6,7 which have been adopted by others.8 Our method repre-
sentational oligonucleotide microarray analysis (ROMA)6,7 utilizes 
representation of the genomic material,9,10 reducing the complexity 
of the genome, increasing hybridization efficiency and increasing the 
signal to noise generated.
We have used ROMA to analyze the copy number fluctuation in a 
set of 72 well-characterized adenocarcinomas of the pancreas to map 
the regions frequently amplified and deleted. The carcinomas anal-
ysed included 22 cell lines, 26 surgically resected primary carcinomas 
and 24 xenografts of surgically resected pancreatic adenocarcinomas 
(independent of the primary tumors analyzed). The primary carci-
nomas were flow sorted to enrich for neoplastic cells, overcoming one 
of the major hurdles in the genetic analyses of pancreatic cancer-low 
neoplastic cellularity.
To increase the number of samples analyzed and to increase the 
probability of finding genomic regions targeted in pancreatic cancer, 
we appended data from 16 primary pancreatic carcinomas and four 
cell lines previously reported by Aguirre and colleagues.11 These 
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Cooperative Human Tissue Network. When matched normal was 
not available (Suppl. Table 1) samples were compared to a normal 
male fibroblast reference DNA. To remove system noise inherent 
to the data statistical methods were used, commonly referred to as 
Circular Binary Segmentation (CBS).21
Regions found frequently altered are more likely to be meaningful 
and the probability of finding any one region altered in multiple 
samples increases with a larger sample set. To increase the sample 
size of (primary tumors especially) we added data from a published 
sample set,11 which included an additional 16 primary pancreatic 
carcinoma samples and six cell lines not included in our initial 
analyses. The data set was configured to our format and cell lines 
analyzed that were present in both datasets were used to cross validate 
the configuration of the data set.
The copy number data for the entire set is shown in Figure 1 as a 
heat map. With the data in this format is it is relatively easy to iden-
tify common regions of alteration. For example, it is clear that the 
p16/CDKN2A (INK/ARF) locus on chromosome 9p, the TP53 locus 
on 17p and the MADH4 locus on 18q are all recurrently deleted. If 
the heat map is used to zoom in it is relatively easy to scan the data 
to identify the genomic coordinates that can be used as breakpoints 
to map candidate genes within the regions altered.
Another common method to visualize alterations identified within 
a large dataset is a frequency plot, or the frequency with which specific 
regions are deleted or amplified. Frequency was calculated for all probes 
by identifying those which varied by 1 SD or more. We compared the 
frequency plots for each group of samples, i.e., primary carcinomas, 
xenografts and cell lines, separately and found that the primary carci-
nomas and the xenografts were very similar and this group of samples 
differed from the cell lines. Therefore the samples were divided into 
two groups during further analysis, one group included the primary 
carcinomas and the xenografts and the second group the cell lines. The 
changes observed in the cell lines may be a manifestation of increased 
genomic instability caused by long term culture. The differences in the 
overall genomic patterns between the primary carcinoma/xenograft 
data and the cell line data are clearly apparent (Fig. 2), with the cell 
lines, as may be expected, having more lesions.
A heuristic algorithm was developed to map regions of interest for 
the identification of candidate genes. We found that although the cell 
lines had many more lesions than primary carcinomas/xenografts, 
the cell line data are of great value in delimiting the epicenter of the 
genetic alterations. The size of the regions identified ranged from 100 
kb to many megabases. The regions identified that were smaller than 
4 MB or that contained fewer than 20 candidate genes are listed in 
Table 1. Once regions have been mapped, candidate genes can easily 
be identified using the outermost array probes as breakpoints. The 
genomic coordinates of these probes, once entered into a site such as 
the UCSC genome browser can be used to identify all genes included 
within the coordinates. Many of the regions we identified have been 
reported in previous studies using lower resolution technologies 
such as CGH and microsatellite markers26,27 and some have been 
reported using technologies with higher resolution.11,28-31 These 
included regions known to be altered in pancreatic cancer and many 
of these regions contain genes that are well characterized such as the 
p16/CDKN2A (INK/ARF) locus on chromosome 9p, the TP53 locus 
on 17p and the MADH4 locus on 18q.
Significantly, we also identified regions that are less well 
characterized and that were not identified earlier as being commonly 
carcinomas did not overlap with our series of cancers and the data 
from the two series are therefore complimentary. The combined 
dataset therefore included a total of 92 unique pancreatic cancer 
samples, the largest dataset publicly available for pancreatic cancer. 
In this dataset we identified the most common regions amplified 
and deleted that are smaller than 4 MB. As expected, we identified 
many genes known to be targeted in pancreatic cancer and other 
cancers as well including p16/CDKN2A (Ink/Arf ), TP53, c-MYC, 
KRAS2, MADH4, TERT, EGFR, ERBB2 and znf217 and a number 
of regions that have not been previously reported. We also report the 
genomic regions that are concurrently altered in the same cancer. 
We report the regions identified and make the data freely accessible 
to the public as supplemental material (www.lucitolab.cshl.edu/
rl_publications.html).
We identified a focal amplification on chromosome 19q13 in 
3 of 27 cell lines and in 5 of 42 primary carcinomas. Candidate 
oncogenes within this region were mapped and the copy number 
data were used to map the boundaries of the common regions of 
mutations or the “epicenter” of the amplification. Cell lines and 
one primary carcinoma, which have the amplicon, were then used 
to determine expression of the 26 candidate genes within the ampli-
fication. From this analysis three candidate genes remained and 
immunohistochemical labeling was used to eliminate one of the 
three, leaving the PAK4 and IXL genes.
The IXL gene has been previously shown to increase cell 
survival.12 The PAK4 gene is a member of the group B p21 activated 
kinases (PAKs), which also include PAK5 and 6. The PAKs are effec-
tors for Rho GTPases that mediate the effects of Rac and Cdc42 
on the cytoskeleton and gene expression.13-17 Of the PAKs, PAK4 
has been shown to promote anchorage independent growth when 
activated.18 In light of this evidence and the fact that other mapped 
amplicons in the cancer genome have identified multiple targets we 
further studied the PAK4 gene as being a second target in the 19q13 
amplicon in pancreatic cancer. We demonstrate that PAK4 protein 
is overexpressed in surgically resected primary pancreatic cancer and 
in pancreatic cancer cell lines that have genomic amplification and 
that the kinase activity in these cells is much higher than it is in 
cells without amplification. Furthermore we show that the PAK4 
gene is not in a mutated oncogenic form but that activation of the 
PAK4 gene is likely to be promoted by KRAS2 gene mutation, a very 
frequent event in pancreatic cancer. The KRAS2 gene was genomi-
cally amplified and overexpressed in several of the pancreatic cancers 
with PAK4 amplification, likely further increasing the ras activity in 
these cells. It is likely that the PAK4 gene cooperates in the growth of 
pancreatic cancer cells alone or in cooperation with other genes from 
the region such as IXL.
Results
We have previously demonstrated that ROMA can be used 
to accurately resolve copy number variations in cancer as well as 
in normal individuals.6,25 The oligonucleotide arrays utilized are 
synthesized by NimbleGen Systems Inc., to our specification and 
have been described in detail in an earlier publication.6
We obtained 22 cell lines from ATCC, 24 xenografts of pancreatic 
adenocarcinomas surgically resected at The Johns Hopkins Hospital 
and 26 primary pancreatic adenocarcinomas, surgically resected at 
the Johns Hopkins Hospital, the Arizona Cancer Center, or from the 
1794 Cancer Biology & Therapy 2008; Vol. 7 Issue 11
Frequent PAK4 activation in pancreatic cancers
©
20
08
 L
an
de
s 
Bi
os
ci
en
ce
. D
o 
no
t d
is
tr
ib
ut
e.
www.landesbioscience.com Cancer Biology & Therapy 1795
frequent genetic events-deletion of the p16/CDKN2A (INK/ARF) 
locus and the amplification of the KRAS2 gene, the c-myc gene, 
or deletion of MADH4 gene. Intriguingly, a rather frequent event 
was the deletion of MADH4 and the amplification of PAK4, which 
occurs in six samples (five of which are primary tumors).
Regions of copy number variation (CNV) in the normal population 
are also uncovered with high resolution CGH techniques.6,22,23,25,32 
Thus, some regions of copy number fluctuation identified that are 
small may be CNVs. We therefore filtered out common CNVs from 
the data utilizing copy number data for 325 normal samples.22,23 
The remaining regions of loss or gain in the carcinomas that contain 
no known genes may yet contain genes proposed by gene finding 
algorithms. However these regions may also contain unknown 
noncoding RNAs, such as miRNAs that could be important for the 
regulation of other gene products.
Almost all regions have multiple gene candidates and analyses to 
remove candidates to determine which candidate is the target of the 
altered in pancreatic or in other cancers. These regions are particu-
larly interesting since they can be used to localize and identify 
genes that, although altered less frequently, may still be important 
for the development and or progression of pancreatic cancer. In 
addition, the pathways altered when these genes are mutated also 
provide additional candidate genes that may be targeted in pancre-
atic cancer.
We also analyzed the data to identify concurrent mutations that 
is to identify genetic changes that tend to occur together in the 
same carcinoma. The constraints for size of the region altered in this 
analysis were removed since we were not concerned with epicenter 
mapping but more so with the genes that were altered. The results 
are shown in Table 2 which represents the number of samples where 
two regions (the intersection on the table) are found altered together 
in the same cancer (a larger version of Table 2 which includes other 
genes altered not listed is available as Table S2). Not surprisingly, 
the alterations that occur together the most frequently are the most 
Figure 1. Copy number of the entire dataset translated as a heat map. In this format each column of the heat map represents a sample. The samples are 
grouped such that tumor cell lines are first, then xenografts followed by primary tumors. Each probe has been reduced to a block and the color of that block 
is representative of that probes copy number, amplifications being a shade of red and deletions being a shade of green. On the X-axis are the samples 
names and the Y-axis places probes in genomic position concatenating all chromosomes to allow visualization of the entire genome.
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shown to increase anchorage independence; however this form of 
PAK4 has rarely been identified in neoplasms.36 None the less, we 
sequenced the PAK4 gene to search for activation mutations in the 
samples shown to have increased PAK4 kinase activity, but we found 
no such mutations (Table 4).
Since PAK4 activity appears to be required for Ras transformation,37 
and KRAS2 gene activation by mutation is such a frequent event in 
pancreatic cancer, the KRAS2 gene was sequenced in samples with 
amplification of the PAK4 gene (Table 4). Codon 12 (the most 
frequently mutated codon) of the KRAS2 gene was mutated in 4 of 
the 5 samples; no other codons were found mutated. In addition, of 
the four samples that have KRAS2 gene mutations, three samples also 
were found to have genomic amplification and overexpression of the 
KRAS2 gene. In all of these samples with oncogenic forms of KRAS2, 
activation of the Ras pathway could be responsible for the activa-
tion of PAK4. Interestingly, the fifth sample, a primary carcinoma 
(JH0007) that had increased expression (Table 3) and increased 
protein (Fig. 4), no mutations in the KRAS2 or PAK4 genes (Table 4) 
were identified. In this sample it is possible that PAK4 is activated by 
a redundant or perhaps some type of RAS independent pathway.
Thus PAK4 is a target of amplification on 19q13 in pancreatic 
cancer and thus is likely relevant to the development and/or the 
progression of pancreatic cancer. The close association of KRAS2 
amplification/activation and PAK4 gene amplification/activation 
suggests that PAK4 protein activation involves Ras activation.
Discussion
Pancreatic cancer is fundamentally a genetic disease. Regions of 
the pancreatic cancer genome that are either deleted or amplified can 
help localize tumor suppressor genes and oncogenes involved in the 
development and progression of this disease. We have analyzed 73 
well-characterized pancreatic cancers samples and appended publicly 
copy number alteration must be performed. To illustrate, we focused 
on a region mapped from the dataset on chromosome 19q13 that 
we and others have found amplified in pancreatic cancer.11,28,30 
In our dataset, with removal of genomic length constraints, this 
region is amplified in 7% of the carcinomas, including four primary 
carcinomas of which one has the highest amplification. Of the 
samples that have this region amplified (Fig. 3A), one of the primary 
carcinomas (JH0007) had the most informative amplicon (Fig. 3B 
green line) defining the epicenter to below 1 Mb (NCBI Build 35 
coordinates chr19: 43,998,060–44,797,349). This region contains 
26 gene candidates.
Since samples with gene amplification, if the gene is biologically 
important in the cancer, are likely to have overexpression of the target 
gene, expression analysis was performed on cell lines and one primary 
tumor (JH0007) that had amplification of this region. Although 
non-target genes may be overexpressed merely as a consequence of 
being gene amplified, it is likely that they will not be overexpressed 
in all samples with gene amplification, whereas the gene targeted 
by the amplification should be overexpressed in all samples. After 
completing this analysis (Table 3), genes that were not consistently 
overexpressed were removed, leaving only three genes, PAF1 (PD2), 
IXL and PAK4. In all samples that have genomic amplification, 
specifically a primary carcinoma which as demonstrated below has 
much higher levels of the PAK4 protein as compared to normal, the 
PAF1, IXL and PAK4 genes are overexpressed. All are viable candi-
dates as oncogenes in the region, since both PAK4 and PAF1 have 
been shown to increase anchorage independent growth under certain 
conditions18,33 and IXL has been shown to increase cell survival.
To determine their relevance to cancer we analyzed the protein 
level of PAK4 and PAF1 (unfortunately to date there is no high 
quality antibody available for the IXL protein) by immunola-
beling of primary tumor JH0007, which had gene amplification. 
Immunolabeling with antibodies to PAK4 protein revealed strong 
diffuse labeling of the neoplastic cells (Fig. 4A and B), with almost all 
of the neoplastic cells intensely labeling. By contrast, non-neoplastic 
pancreatic tissue did not show any labeling. Immunolabeling with 
antibodies to the PD2 (PAF1) protein revealed diffuse labeling of the 
neoplastic as well as labeling of the normal cells (Fig. 4C and D). The 
levels of PD2 protein (PAF1) being equivalent in the normal allowed 
its removal as a candidate oncogene in this particular environment, 
which left PAK4 and IXL as the target genes of amplification. It is 
possible that there are two oncogenes within the region which may 
cooperate in pancreatic carcinogenesis as this phenomenon has 
been observed in other genomic regions in other cancer types.34,35 
Therefore we further investigated the activation of PAK4.
The PAK4 protein, one of the group B PAKs, can promote 
anchorage independent growth of neoplastic cells when activated.18 
Activation of PAK4 can occur through amplification, point muta-
tions, or as a result of activation of normal cellular pathways 
including the Ras pathway. To determine whether the PAK4 protein 
is activated in these cancers we performed an in-vitro kinase assay on 
extracts from cell lines with the amplicon Figure 5. In comparison to 
a pancreatic cell line that did not have amplification or overexpres-
sion of this gene, the cell lines with an amplification had 10–15 times 
more protein and 8–10 fold more kinase activity; demonstrating that 
the protein is active in samples with gene amplification and increased 
protein level. The activation of PAK4 by gene mutation has been 
Figure 2. A frequency plot, calculated from the copy number of the entire 
dataset. The cumulative number of lesions were calculated probe by probe 
over all experiments and then normalized based on the sample size for the 
set utilized to calculate the frequency. The two sets utilized for this analysis 
were cell lines as one set and primary tumors and xenografts as a second 
set. Amplifications and deletions were calculated separately, for primary 
tumors and xenografts the amplifications are red and deletions are green, 
whereas both amplifications and deletions for the cell line set are light grey. 
The X-axis is the genomic position, concatenating the chromosomes to allow 
visualization of the entire genome and the Y-axis is the frequency that the 
copy number abberations are observed in the specific dataset.
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Table 1 Regions identified from the copy number dataset that were altered in more than one sample
The table is divided in two, separating amplifications and deletions. For each the first column is the May 04 genomic coordinates (Build 35), the second column is the number of primary tumors and third column is the 
number of cell lines that the aberration is found in. The fourth column is known genes to be involved in cancer and the fifth column is a possible candidate based on function. The last column has a star marking regions 
that have few if any genes. The raw and segmented copy number data for the entire dataset is available as supplemental data (http://lucitolab.cshl.edu/rl_publications.html).
Frequent PAK4 activation in pancreatic cancers
Table 2 Genomic regions altered within the same sample
Along the left side are the names of known genes identified in the dataset as having alterations. Along the top are the same genes forming a matrix. The color corresponds to the copy number, deletion (green) or amplified 
(red). The second column is the number of samples that have either amplification or deletion of the region in question. The constraints of size imposed for epicenter mapping were removed for this analysis. Other genes 
that were found altered not listed in Table 1 identified in this analysis due to the removal of size constraints are available as Table S2 in supplemental data.
others have shown that copy-neutral (i.e., having two copies) and 
copy-gain (i.e., having more than two copies) forms of allelic loss 
accounted for a significant proportion of losses of heterozygosity in 
cancer.38,39 Such alterations would not be detected in our analyses.
available data for 16 more samples. We report regions recurrently 
amplified or deleted within the dataset as well as regions altered 
concurrently within the same sample. One limitation of ROMA is 
that it only provides information on copy number.38 Beroukim and 
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other amplified genes (unpublished observation). Thus, we believe 
that PAK4 and IXL are the most viable targets for the chromosome 
19q13 amplification.
We have shown that in addition to there being overexpression, 
that there is increased protein and that the kinase activity of PAK4 is 
elevated. The inhibition of kinase activity of group II Pak’s, of which 
PAK4 is a member, is not as well understood as is the auto inhibitory 
domain of the group I Pak’s. However recent evidence suggests that 
the inhibition of PAK4 kinase may be similar to that of the group 
I Paks where a segment of the protein folds over to inhibit kinase 
activity. This inhibition42 possibly requires associating with another 
factor such as Cdc42 for activation. It is known that the PAK4 gene 
is mutated in some cancers36 and when mutated/activated, PAK4 
can promote anchorage independent growth.18 We have functionally 
validated the PAK4 gene as the target of amplification in pancreatic 
cancer based on its increased functional activity. We have demon-
strated that the PAK4 protein can be active in pancreatic cancer cells 
without the necessity of mutation and that the activation of PAK4 
can be a consequence of KRAS2 gene mutation, often in conjunc-
tion with KRAS2 gene amplification and overexpression, as well as 
a possible Ras independent mechanism. The PAK4 protein through 
its interation with Cdc42 is involved in altering the cytoskeleton by 
promoting the formation of filopodia.13 We propose that activation 
of PAK4 is critical to neoplastic pancreatic cells as they transition to 
invasiveness. We are currently investigating this potential.
Pancreatic cancer is not the only type of cancer that has frequent 
amplification of this region. This region is amplified in other tumor 
types including ovarian and breast cancer. In addition, the kinase 
activity of PAK 4 is increased in some breast cancer samples with 
genomic amplification (unpublished observation Lucito). The PAK4 
gene is frequently overexpressed without the presence of gene acti-
vating mutation in many tumor types other than pancreatic cancer37 
suggesting that this gene is an important target during carcinogen-
esis. We are currently continuing our studies of PAK4 involvement in 
pancreatic cancer including the possible cooperation with IXL.
In summary we have amassed the largest CGH dataset for pancre-
atic cancer and present the regions commonly altered. This dataset 
was used to identify candidate target genes within an amplicon on 
chromosome19q13 and other methods were utilized to identify the 
target of amplification, demonstrating the value of the dataset. The 
dataset we present will be particularly useful for the pancreatic cancer 
community as efforts are undertaken to sequence the pancreatic 
cancer genome.
Materials and Methods
Materials. Enzymes; BglII, T4 DNA ligase, were supplied by 
new England Biolabs. Primers were supplied by Sigma Genosys. 
Cot1 DNA and tRNA were supplied by invitrogen. The Megaprime 
labeling kit, Cy3-conjugated dCTP and Cy5-conjugated dCTP 
were supplied by Amersham-Bioscience. Taq polymerase (Eppendorf 
mastermix (2.5X)) was supplied by Eppendorf. Centricon YM-30 
filters were supplied by Amicon and formamide was supplied by 
Amresco. Phenol: chloroform was supplied by Sigma. NimbleGen 
photoprint arrays were synthesized by NimbleGen Systems Inc., 
Design of the ROMA array was described previously.6
ROMA. Arrays were described previously.6 In brief the arrays are 
based on representational techniques and thus all oligonucleotides 
We identified a recurrent amplicon on chromosome 19q13 and 
we show that, in addition to the IXL gene, this amplicon contains a 
second target gene. This gene, PAK4, is a p21 activated kinase, one 
of the lesser studied members of the PAK family, especially in the 
involvement of the ras pathway.
Our data, at present is the largest CGH pancreatic tumor dataset 
and we have made this resource available to the cancer community 
(http://lucitolab.cshl.edu/rl_publications.html) to allow others to 
benefit from the interpretation of this valuable dataset and to iden-
tify other genes involved in the progression of pancreatic cancer. 
We anticipate that this dataset will be particularly useful as groups 
plan and undertake large-scale sequencing of the pancreatic cancer 
genome.40,41 The genes included within amplicons and deletions 
can be prioritized for sequencing, or, conversely, genes found to be 
mutated in pancreatic cancer can be prioritized for follow-up studies 
if they lie within a recurrent amplification or deletion.
Many more regions of the genome were found altered than 
are reported in Table 1. Because of space limitations we have only 
reported regions that have an epicenter of less that 4Mb or fewer than 
20 genes. The constraints of size were removed to determine how 
frequently specific regions were altered in the same samples. The data 
were presented as pairs, or how many samples any two genes would 
be found altered.
There are also small regions (listed in Table 1) likely to be legiti-
mate targets of amplification or deletion in the cancer since they have 
been found altered in more than one sample. These small regions are 
of particular interest since most contain few if any genes.
Given the number of normal samples (325, see methods) used to 
remove normal genetic variation (i.e., CNVs) it is unlikely that any 
remaining regions were common CNVs. An interesting possibility 
is that these regions could be CNVs that associate with hereditary 
pancreatic cancer and may contain a tumor suppressor.32 As a conse-
quence these regions would be expected to be enriched in the tumor 
population. Further analyses of possible frequency differences for 
these regions and the normal population are ongoing.
Although we observed significant agreement in the copy number 
profile frequency plots of cell lines and primary carcinomas, there 
were significant disparities (see Fig. 2), which could be caused 
by the cultured cells non-specifically accumulating mutations or 
accumulating mutations which help the cells adapt to tissue culture 
conditions. Our algorithm to identify regions took this into account. 
We found that the data from the cell lines were very informative, 
often having smaller lesions than primary carcinomas and xeno-
grafts. These smaller regions can be used to delimit more finely the 
epicenter of mutation, but should not be used to identify a region of 
importance. There are of course primary carcinoma samples which 
have relatively small lesions, an example being the region on chromo-
some 19 harboring several gene candidates.
Most recently the IXL, SUPT5H and ZFP36 genes were identified 
as targets of this region and all three were shown to have an effect on 
cell growth.12 Although we did not, Kuuselo and colleagues deter-
mined that PAK4 is amplified to a lesser extent and have excluded 
PAK4 from their analysis. Our expression analysis removes SUPT5H 
and ZFP36 as critical candidates since they are not consistently 
overexpressed, leaving IXL, PAK4 and PAF1. PAF1 was removed as 
a viable candidate gene because we found that the protein levels did 
not correlate with mRNA levels, a finding we have observed with 
Frequent PAK4 activation in pancreatic cancers
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determined. DNA was labeled as described with minor changes.19 
Briefly, 2 ug of DNA template was placed (dissolved in TE at pH 
8) in a 0.2-mL PCR tube. 5 μL of random nonamers from Sigma 
Geneosys were added, the volume brought up to 50 μL with dH2O 
and mixed. The tubes were placed in Tetrad at 100°C for 5 min, 
then on ice for five minutes. To this 10 μL of buffer two from NEB 
and 6 ul of dNTP mix (Adenine, guanine and thiamine are 1.2 mM 
and cytosine is 0.6 Mm), 5 μL of label (Cy3-dCTP or Cy5-dCTP) 
and 1 μL of NEB Klenow fragment were added. Procedures were 
followed as reported previously.20 Arrays were scanned with an Axon 
GenePix 4000B scanner set at a pixel size of 5 μm. GenePix Pro 4.0 
software was used to quantify the intensity for the arrays. Array data 
were imported into S-PLUS for further analysis. Measured intensi-
ties without background subtraction were used to calculate ratios. 
Data were normalized using an intensity-based lowest curve fitting 
algorithm.
Segmentation. To decrease or remove probe to probe variation 
various algorithms can be used. We utilize an algorithm developed 
by Adam Olshen and colleagues21 called Circular Binary Briefly, 
the algorithm recursively splits chromosomes into subsegments of 
at least three probes in size by testing the change-points until none 
can be found as significant within the existing subsegments, as deter-
mined by p-value (a = 0 .05) obtained through a hybrid approach. 
A split point will be removed if the difference between the means of 
adjacent segments is less than 1.0 SD of the 2.5%-trimmed data. The 
code for this algorithm is freely available (http://bioconductor.org/
packages/2.1/bioc/html/DNAcopy.html).
Copy number data from the Aguirre et al. data set were segmented 
with methods developed by Dr. Adam Olshen.21 Frequency plots of 
the data were generated by identifying probes that were 1 SD above 
and calculating the frequency this occurs.
CNV subtraction. When utilizing high resolution arrays, germ-
line CNVs will be identified when comparing cancer to normal from 
a different person. In the present study, common CNVs found in 
the normal population were filtered out utilizing a set of 325 normal 
patients.22,23 The dataset if based on all probes would require a 
large data frame to represent all samples and would drastically slow 
down computing time. Much of the data from the genome reports 
non-events or vast regions without CNVs. Therefore, the probe 
based data is reduced to event based data. In other words only the 
CNVs, location and ratio, are represented in a file, thereby drasti-
cally reducing size without decreasing the information content. This 
transformation was performed for both the pancreatic cancer and 
the normal filter sample datasets and filtration processed as follows. 
The data can be thought of being reduced to binary, either altered 
or not altered. The test set is compared to the normal set, if a region 
altered in the test set is found altered in the normal set, this region is 
removed from the test set.
Expression analysis. Total RNA was isolated from the cell lines 
and from the primary tumor using the Qiagen RNeasy kit and the 
integrity was checked on an Agilent bioanalyzer. Five ug of total RNA 
was used to produce ds cDNA using the Superscript Choice Labeling 
Kit (Invitrogen). The product was used as template to produce 
biotynilated cRNA with the Bioarray high yield RNA transcript 
labeling kit (Enzo). Twenty ug of biotynilated cRNA was fragmented 
with reagents from the Superscript Choice Labeling kit. Control 
oligos (Affymetrix) were spiked into the fragmented product and 
map to BglII fragments that are within the representations size range 
of 200–1000 bp. The array was esigned to June 2002 (NCBI Build 
30) and the coordinates have been updated to May 2004 (NCBI 
Build 35). There are over 80,000 features on the array and these 
are scattered across the genome resulting in an average resolution 
of 30 kb. All samples without a matched reference were compared 
to CHP-SKN-1 a normal male fibroblast cell line we use routinely 
for all unmatched sample analysis. Sample preparation, BglII repre-
sentations, has been described previously.19 Minor changes in the 
protocol are as follows: as few as four 250-μL tubes were used for 
each sample for amplification of the representation each with a 100 
ul volume reaction. An equal number of tubes were used for refer-
ence for each sample that was co-amplified. The cycle conditions 
were 95°C for 1 min, 72°C for 3 min, for 20 cycles, followed by a 
10-min extension at 72°C. The contents of the tubes were pooled 
when completed. Representations were cleaned by phenol: chloro-
form extraction, precipitated, resuspended and the concentration 
Figure 3. Segmentation values for four samples with genomic amplification 
of the 19q13 region. (A) shows the genomic profile for four samples with 
amplification of 19q13 region with an arrow pointing to chromosome 19. 
(B) shows the region of interest on the q-arm of four tumors. The X-axis is the 
chromosome position (divided by 106) and the Y-axis is the log ratio of the 
segmentation value.
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the material was hybridized to U133 Plus 
arrays, washed and scanned according to 
Affymetrix protocols (https://www.affyme-
trix.com/support/downloads/manuals/
expression_s2_manual.pdf ). Probe level 
analysis was done using the “affy” package 
from the Bioconductor www.bioconductor.
org. Briefly the data intensity values for the 
probe set were extracted by applying the 
RMA algorithm.24 Ratios were calculated 
on log base two scale.
Immunoblotting. A 10 cm plate 
of cells were lysed in RIPA buffer and 
collected after scraping. Equal amounts 
of protein (15 ug) were separated on 10% 
SDS-polyacrylamide gels and transferred 
to nitrocellulose membranes. The blots 
were probed with primary antibodies 
against human PAK4 (Cell Signaling 
Tech. cat #3242) the control Ab being 
Lamin A/C (Santa Cruze Biotech.), both 
at 1:1000. Blots were then probed with 
HRP-conjugated secondary antibodies and 
visualized by chemiluminescence (Santa 
Cruz Biotech).
Immunolabeling. All immunolabeling 
was performed at room temperature and 
Table 3  Affymetrix expression data for those genes within the chromosome 19q13 epicenter of amplification
Expression analysis was performed on the U133 Plus2 arrays. The reference sample was the cell line HPDE which is normal human pancreatic ductal epithelium. The first five columns of the table are as follows; start of 
the gene, end of the gene, accession ID for the gene. The remaining columns are expression data (log scale) for particular cell lines or tumor as follows; Colo320, Colo587, E3GS2.4, PANC1, SU.86.86, JH0007 as compared 
to the cell line HPDE. The cell lines in blue do not have genomic amplification of the region. The Accession Ids in red mark the genes with the most consistent expression pattern.
Frequent PAK4 activation in pancreatic cancers
Figure 4. Immunohistochemistry for two genes PAF1 and PAK4 in a tumor with the chromosome 19 ampli-
con. (A and B) show labeling for PAK4 and (C and D) show labeling for PAF1. (B and D) are sections 
with perineural invasion. Arrows point to tumor and arrow heads point to normal when appropriate to 
demonstrate high level of protein in normal.
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with primary antibody. Following removal of primary antibody the 
sections were incubated for 15 min in BioCare Mach 4* Mouse Probe 
rinsed in buffer and then incubated for 15 min in MR HRP-Polymer. 
After rinsing in buffer, the sections were then incubated in a freshly 
prepared mixture of diaminobenzidine (DAB) and buffer substrate 
solution for 5 min. Sections were then counterstained with hema-
toxylin and blued in Richard Allen Bluing Reagent TM, dehydrated 
in a graded series of ethanols and xylene and coverslipped. Slides were 
reviewed by light microscopy.
Immunoprecipitation and kinase assay. Methods were similar to 
those used in Bagrodia et al. with minor changes.14 Briefly, cells were 
lysed in 40 mM Hepes (pH 7.4), 1% Nonidet P-40, 100 mM NaCl, 
1 m MEDTA, 10 ug/ml leupeptin and 10 ug/ml PMSF and centri-
fuged at 12,000 xg for 15 min at 4°C. Lysates were precleared with 
IgG and protein A/G PLUS agarose (santa cruz biotech cat #sc2003). 
10 ul of PAK4 Ab (Cell Signalling Tech. cat #3242) was added to 
the precleared lysates and incubated on ice for 60 min followed by 
protein A/G PLUS agarose (Santa Cruz Biotech cat #sc2003) for 30 
min. the immunoprecipitate was spun and washed with lysate buffer 
four times and then washed with 2X phosphorylation buffer (10 
mM MgCl2, 40 mM Hepes (pH 4.7)). To the tube the following 
was added; 5 ug myelin basic protein (Sigma cat# M1891) 10 uCi 
of gamma 32P ATP (3000 Ci/mmol) and 20 uM ATP in 30 ul total 
volume for 20 minutes at RT. Protein gel loading buffer was added 
and the samples was run on SDS PAGE, transferred to a membrane 
and autoradiography performed.
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